Major Events - Xian Dao Intelligent (00470) has set the offer price for H-shares at HKD 45.80, with the sale volume adjustment rights fully exercised [1] - Lexin Outdoor (02720) has seen a public offering subscription rate of 3654.23 times, with a per share pricing of HKD 12.25 [1] - Aixin Yuan Zhi (00600) has achieved a public offering subscription rate of 104.82 times, with a final offer price of HKD 28.2 per share [1] - Shandong Xinhua Pharmaceutical (00719) has obtained the registration certificate for glucosamine sulfate capsules [1] - United Pharmaceutical (03933) has passed the consistency evaluation for roxithromycin capsules [1] - InnoCare Pharma (03696) has reached several drug development projects in the central nervous system and autoimmune disease fields with Kangzhi Pharmaceutical, valued at tens of millions of HKD [1] - Sunshine Insurance (06963) subsidiary plans to increase capital to Sunshine Asset Management (Hong Kong) for a total of no more than HKD 1 billion [1] - Crystal Tech Holdings (02228) has established a robotics laboratory in BASF, receiving top endorsement from the chemical industry for global technological leadership [1] - Youjia Innovation (02431) has newly secured designated projects in intelligent driving and intelligent cockpit [1] - China Resources Pharmaceutical (03320) is considering the potential sale of approximately 17.87% equity in Tianmai Biotechnology [1] Operating Performance - Hong Kong Telecom-SS (06823) reported a profit attributable to shareholders of HKD 5.286 billion for 2025 [1] - Pop Mart (09992) has achieved global sales of over 400 million units across all IP and product categories in 2025 [1] - Longfor Group (00960) reported a contract sales amount of HKD 2.45 billion in January [1] - China Jinmao (00817) recorded a signed sales amount of HKD 7.603 billion in January, an increase of 13.56% year-on-year [1] - New天绿色能源 (00956) completed a power generation volume of 1.7393 million MWh in January, a year-on-year increase of 15.25% [1] - Dekang Agriculture and Animal Husbandry (02419) sold 1.04236 million pigs in January [1] - China Oriental Education (00667) has issued a profit warning, expecting a year-on-year profit increase of 46% to 51% for the 2025 fiscal year [1] - China Nuclear International (02302) has issued a profit warning, expecting gross profit for 2025 to reach no less than approximately HKD 260 million [1] - Mingyuan Cloud (00909) has issued a profit warning, expecting net profit attributable to shareholders for 2025 to be approximately HKD 26.9 million to HKD 32.8 million, turning from loss to profit year-on-year [1]

Core Viewpoint - The company has successfully passed the consistency evaluation for the generic drug Roxithromycin capsules (150mg) by the National Medical Products Administration of China, which will strengthen its position in the anti-infection sector [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Zhuhai United Pharmaceutical Co., Ltd., has received approval for Roxithromycin capsules, marking it as the first company to pass this evaluation for this dosage form [1] - Roxithromycin is a second-generation macrolide antibiotic known for its good acid resistance, broad antibacterial spectrum, strong tissue penetration, and low incidence of adverse reactions [1] Group 2: Clinical Applications - The drug is clinically applicable for treating infections caused by Roxithromycin-sensitive pathogens in areas such as otolaryngology, respiratory tract, skin and soft tissue, and urogenital infections [1] Group 3: Market Position and Future Prospects - The product is listed as a Class B drug in the National Medical Insurance Directory (2025 version), which may enhance its market accessibility [1] - The approval is expected to help the company consolidate its competitive advantage in the anti-infection field and drive further product development, potentially leading to greater returns for the company and its shareholders [1]

Core Viewpoint - The company has successfully passed the consistency evaluation for the generic drug Roxithromycin capsules (150mg) through the National Medical Products Administration of China, reinforcing its competitive position in the anti-infection sector [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Zhuhai United Pharmaceutical Co., Ltd., has received approval for Roxithromycin capsules, marking it as the first enterprise to pass the consistency evaluation for this formulation [1] - Roxithromycin is a second-generation macrolide antibiotic known for its acid resistance, broad antibacterial spectrum, strong tissue penetration, and low incidence of adverse reactions [1] Group 2: Clinical Applications - Roxithromycin capsules are clinically applicable for treating infections caused by Roxithromycin-sensitive pathogens, including those affecting the ear, nose, throat, respiratory tract, skin, soft tissues, and urogenital tract [1] Group 3: Market Position and Future Outlook - The product is listed as a Class B drug in the National Medical Insurance Directory (2025 version), which is expected to enhance the company's market position in the anti-infection field [1] - The company aims to continue its commitment to new product development, anticipating greater returns for itself and its shareholders [1]

Core Viewpoint - The approval of the roxithromycin capsules by the National Medical Products Administration of China enhances the company's competitive position in the anti-infection sector and is expected to generate greater returns for the company and its shareholders [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Zhuhai United Pharmaceutical Co., Ltd., has successfully passed the consistency evaluation of the roxithromycin capsules (150mg) [1] - Roxithromycin capsules are a second-generation macrolide antibiotic known for their acid resistance, broad antibacterial spectrum, strong tissue penetration, and low incidence of adverse reactions [1] - The product is currently listed as a Class B drug in the National Medical Insurance Directory (2025 version) [1] Group 2: Market Position and Future Prospects - The company is the first to pass the consistency evaluation for the roxithromycin capsule formulation [1] - This approval will further help the company consolidate its advantageous position in the anti-infection field [1] - The company is committed to ongoing new product development, which is anticipated to create greater benefits for the company and its shareholders [1]

Core Viewpoint - The company, Buchang Pharma, has confirmed its involvement in the production of antibiotic products, including specific types of antibiotics currently in its portfolio [2] Group 1: Business Overview - The company's antibiotic product range includes Roxithromycin capsules, Erythromycin ethylsuccinate tablets, Erythromycin tablets, and Erythromycin enteric-coated tablets [2] - Future developments regarding military pharmaceuticals will be disclosed through the company's regular reports and announcements [2]